Background: Survival rates among childhood cancer survivors (CCSs) have significantly risen in the last 40 years due to substantial improvements in treatment protocols. However, this improvement has brought with it serious late effects that frequently involve the endocrine system. Of the endocrine disorders, GH deficiency (GHD) is the most common among CCSs as a consequence of a history of cancers, surgery, and/or radiotherapy involving the hypothalamo-pituitary region. Methods: A comprehensive search of English language articles regardless of age was conducted in the MEDLINE database between December 2018 and October 2019. We selected all studies on GH therapy in CCSs during the transition age regarding the most challenging topics: when to retest; which diagnostic tests and cut-offs to use; when to start GH replacement therapy (GHRT); what GH dose to use; safety; quality of life, compliance and adherence to GHRT; interactions between GH and other hormonal replacement treatments. Results: In the present review, we provide an overview of the current clinical management of challenges in GHD in cancer survivors in the transition age. Conclusions: Endocrine dysfunction among CCSs has a high prevalence in the transition age and increase with time. Many endocrine disorders, including GHD, are often not diagnosed or under-diagnosed, probably due to the lack of specialized centers for the long-term follow-up. Therefore, it is crucial that transition specialized clinics should be increased in terms of number and specific skills in order to manage endocrine disorders in adolescence, a delicate and complex period of life. A multidisciplinary approach, also including psychological counseling, is essential in the follow-up and management of these patients in order to minimize their disabilities and maximize their quality of life.

GH deficiency in cancer survivors in the transition age: diagnosis and therapy / Sbardella, Emilia; Crocco, Marco; Feola, Tiziana; Papa, Fortuna; Puliani, Giulia; Gianfrilli, Daniele; Isidori, Andrea M; Grossman, Ashley B. - In: PITUITARY. - ISSN 1386-341X. - 23:(2020), pp. 432-456. [10.1007/s11102-020-01052-0]

GH deficiency in cancer survivors in the transition age: diagnosis and therapy

Sbardella, Emilia
;
Feola, Tiziana;Puliani, Giulia;Gianfrilli, Daniele;Isidori, Andrea M;
2020

Abstract

Background: Survival rates among childhood cancer survivors (CCSs) have significantly risen in the last 40 years due to substantial improvements in treatment protocols. However, this improvement has brought with it serious late effects that frequently involve the endocrine system. Of the endocrine disorders, GH deficiency (GHD) is the most common among CCSs as a consequence of a history of cancers, surgery, and/or radiotherapy involving the hypothalamo-pituitary region. Methods: A comprehensive search of English language articles regardless of age was conducted in the MEDLINE database between December 2018 and October 2019. We selected all studies on GH therapy in CCSs during the transition age regarding the most challenging topics: when to retest; which diagnostic tests and cut-offs to use; when to start GH replacement therapy (GHRT); what GH dose to use; safety; quality of life, compliance and adherence to GHRT; interactions between GH and other hormonal replacement treatments. Results: In the present review, we provide an overview of the current clinical management of challenges in GHD in cancer survivors in the transition age. Conclusions: Endocrine dysfunction among CCSs has a high prevalence in the transition age and increase with time. Many endocrine disorders, including GHD, are often not diagnosed or under-diagnosed, probably due to the lack of specialized centers for the long-term follow-up. Therefore, it is crucial that transition specialized clinics should be increased in terms of number and specific skills in order to manage endocrine disorders in adolescence, a delicate and complex period of life. A multidisciplinary approach, also including psychological counseling, is essential in the follow-up and management of these patients in order to minimize their disabilities and maximize their quality of life.
2020
adolescence; cancer; growth hormone; survivor; transition
01 Pubblicazione su rivista::01a Articolo in rivista
GH deficiency in cancer survivors in the transition age: diagnosis and therapy / Sbardella, Emilia; Crocco, Marco; Feola, Tiziana; Papa, Fortuna; Puliani, Giulia; Gianfrilli, Daniele; Isidori, Andrea M; Grossman, Ashley B. - In: PITUITARY. - ISSN 1386-341X. - 23:(2020), pp. 432-456. [10.1007/s11102-020-01052-0]
File allegati a questo prodotto
File Dimensione Formato  
Sbardella_GH-deficiency_2020.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 810.24 kB
Formato Adobe PDF
810.24 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1408663
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact